AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34111898
Drug: Both Robot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both Robot and Tablet
Trial: 36372250
Drug: Highly purified
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highly purified EPA (1800 mg/day)
Trial: 38656736
Drug: BI 1358894
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1358894 (100 mg)
Trial: 38421881
Drug: Ensartinib 225
RxNorm normalized name: Ensartinib
DrugBank: Ensartinib (DB14860)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ensartinib 225 mg orally once daily
Trial: 35315257
Drug: Esaxerenone 5-mg
RxNorm normalized name: Esaxerenone
DrugBank: Esaxerenone (DB15207)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Esaxerenone 5-mg orally disintegrating tablet (ODT) taken with water
Trial: 35315257
Drug: Esaxerenone 5-mg
RxNorm normalized name: Esaxerenone
DrugBank: Esaxerenone (DB15207)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Esaxerenone 5-mg orally disintegrating tablet (ODT) taken without water
Trial: 35315257
Drug: Conventional oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oral tablet (5-mg)
Trial: 33180929
Drug: Vi‐tetanus toxoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vi‐tetanus toxoid conjugate (Vi‐TT) vaccine
Trial: 33180929
Drug: Vi‐polysaccharide (Vi‐PS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vi‐polysaccharide (Vi‐PS) vaccine
Trial: 33180929
Drug: Vi‐TT and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vi‐TT and Vi‐PS vaccines (combined analysis)
Trial: 34506037
Drug: Prophylactic closed-incision
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic closed-incision negative pressure wound therapy dressing
Trial: 35724467
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no prophylactic treatment)
Trial: 35489376
Drug: NVX-CoV2373 vaccine
RxNorm normalized name: SARS-CoV-2 NVX-CoV2373 vaccine, recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVX-CoV2373 vaccine (5 µg SARS-CoV-2 recombinant spike protein with 50 µg Matrix-M adjuvant)
Trial: 33517233
Drug: Nicotine cigarettes
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine cigarettes (various contents: 1.3, 2.3, 5.5, 11.2, and 17.4 mg/g)
Trial: 33517233
Drug: Very Low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very Low Nicotine Content (VLNC) cigarettes (0.4 mg/g)
Trial: 35388471
Drug: Nirmatrelvir/ritonavir (300/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nirmatrelvir/ritonavir (300/100 mg b.i.d.)
Trial: 32554835
Drug: Traditional Persian
RxNorm normalized name: PERUVIAN BALSAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Persian medicine (TPM) strategies including exercise, nutrition, massage, bathing, aromatherapy, and sleeping.
Trial: 32553329
Drug: Second-generation drug-eluting
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-generation drug-eluting stents (DES)
Trial: 32750393
Drug: 1-month dual
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1-month dual anti-platelet therapy (DAPT) followed by 23-month ticagrelor monotherapy
Trial: 32750393
Drug: 12-month dual
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 12-month dual anti-platelet therapy (DAPT) followed by 12-month aspirin monotherapy
Trial: 35289296
Drug: Triple Therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple Therapy (TT)
Trial: 35822607
Drug: LIA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIA with a new cocktail containing ropivacaine, diprospan, and morphine
Trial: 32349698
Drug: Social Activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social Activity Therapy (SAT)
Trial: 35977911
Drug: Beta-alanine supplementation
RxNorm normalized name: beta-alanine
DrugBank: beta-Alanine (DB03107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-alanine supplementation (3.2 g/day for 12 weeks)
Trial: 35665223
Drug: Tangeretin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tangeretin (200 mg/day)
Trial: 33213494
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human erythropoietin (rHu‐EPO) 10000 IU subcutaneous injection after operation and once daily for the next week
Trial: 33808652
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K (400 µg MK‐7/day) and vitamin D3 (80 µg/day)
Trial: 33754184
Drug: Enteral resorbable
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral resorbable diet (ED) with peristalsis-inhibiting medication
Trial: 33100212
Drug: Topical cream
RxNorm normalized name: Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cream of Malva sylvestris extract, applied twice daily for 4 weeks.
Trial: 33100212
Drug: Placebo cream,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream, applied twice daily for 4 weeks.
Trial: 33188138
Drug: Intramuscular ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular ceftriaxone followed by 5 days of azithromycin and metronidazole (IA)
Trial: 33957190
Drug: Oral Health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Health Education Program combined with routine dental treatment (OHEPDT)
Trial: 33957190
Drug: Dental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental treatment alone (DT)
Trial: 33931498
Drug: Carboplatin (AUC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (AUC 5), Paclitaxel (175 mg/m2), and Bevacizumab (15 mg/kg) for six 3-weekly cycles followed by Bevacizumab single agent (15 mg/kg) until progression or unacceptable toxicity
Trial: 34154431
Drug: 4-month physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-month physical activity group program (two walks per week and a monthly visit to a sociocultural facility)
Trial: 35246243
Drug: Diacerein 50
RxNorm normalized name: Diacerein 50 mg and glucosamine sulfate potassium chloride 1.5 g oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diacerein 50 mg once-daily (n=18)
Trial: 32946077
Drug: Tadalafil (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil (20 mg, Cialis®)
Trial: 32946077
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Tadalafil and Placebo)
Trial: 37034122
Drug: Lobeglitazone monotherapy
RxNorm normalized name: lobeglitazone
DrugBank: Lobeglitazone (DB09198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lobeglitazone monotherapy
Trial: 34812472
Drug: Combination taping
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination taping
Trial: 35720389
Drug: Intranasal anti-SARS-CoV-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal anti-SARS-CoV-2 RBD IgY
Trial: 34259850
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (electrotherapy and oral medication)
Trial: 35443106
Drug: AZD7442 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD7442 (300 mg, two consecutive intramuscular injections of tixagevimab and cilgavimab)
Trial: 35443106
Drug: AZD7442 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD7442 (300 mg)
Trial: 36890535
Drug: Nurse-administered injections
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-administered injections
Trial: 35550707
Drug: 6% Pueraria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% Pueraria mirifica vaginal gel
Trial: 32081463
Drug: mirvetuximab soravtansine
RxNorm normalized name: MIRVETUXIMAB SORAVTANSINE
DrugBank: Mirvetuximab soravtansine (DB12489)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mirvetuximab soravtansine (6 mg/kg, adjusted ideal body weight) and bevacizumab (15 mg/kg)
Trial: 36670359
Drug: Clarithromycin, esomeprazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin, esomeprazole, and amoxicillin
Trial: 36670359
Drug: Levofloxacin, esomeprazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin, esomeprazole, and amoxicillin
Trial: 35091442
Drug: Ponatinib 45
RxNorm normalized name: PONATinib 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponatinib 45 mg once daily
Trial: 36163905
Drug: Ponatinib 30
RxNorm normalized name: PONATinib 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponatinib 30 mg once daily
Trial: 36163905
Drug: Ponatinib 15
RxNorm normalized name: PONATinib 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponatinib 15 mg once daily
Trial: 34407543
Drug: Ponatinib 45
RxNorm normalized name: PONATinib 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponatinib 45 mg and 30 mg (reduced to 15 mg upon response)
Trial: 32928279
Drug: GV‐971 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GV‐971 600 mg
Trial: 32928279
Drug: GV‐971 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GV‐971 900 mg
Trial: 33538686
Drug: Standard oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oxygen therapy, titrated to the British Thoracic Society's peripheral oxygen saturation targets
Trial: 34967444
Drug: Best Possible
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best Possible Medication History (BPMH) approach
Trial: 36099408
Drug: Preoperative respiratory
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative respiratory therapy (EG)
Trial: 33813141
Drug: Flexyn2a bioconjugate
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flexyn2a bioconjugate vaccine
Trial: 32027212
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (intensive medical therapies)
Trial: 36378059
Drug: Liu-zi-jue plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liu-zi-jue plus conventional therapy
Trial: 33415873
Drug: Acupuncture plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture plus medication (1% lidocaine 4 mL after acupuncture)
Trial: 33415873
Drug: Simple medication
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple medication (1% lidocaine 30 mL)
Trial: 33934988
Drug: Volatile Anesthetics
RxNorm normalized name: coal tar pitch volatiles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volatile Anesthetics exposure quantified using area under the end-tidal expired anesthetic agent versus time curves
Trial: 36098133
Drug: Bimagrumab 210
RxNorm normalized name: Bimagrumab
DrugBank: Bimagrumab (DB12584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimagrumab 210 mg
Trial: 36098133
Drug: Bimagrumab 700
RxNorm normalized name: Bimagrumab
DrugBank: Bimagrumab (DB12584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimagrumab 700 mg
Trial: 36098133
Drug: Bimagrumab 70
RxNorm normalized name: Bimagrumab
DrugBank: Bimagrumab (DB12584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimagrumab 70 mg
Trial: 32347763
Drug: Dupilumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab (300 mg subcutaneously weekly or every 2 weeks)
Trial: 32347763
Drug: Dupilumab with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab with concomitant topical corticosteroids (TCS)
Trial: 32347763
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids (TCS) alone
Trial: 35842816
Drug: Ivermectin/praziquantel (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin/praziquantel (0.2 mg/kg)
Trial: 35842816
Drug: Moxidectin/praziquantel (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxidectin/praziquantel (0.4 mg/kg)
Trial: 35325108
Drug: CC‐486 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC‐486 (oral azacitidine) 300 mg daily in a 2 weeks on/2 weeks off schedule
Trial: 34097069
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) along with Pregabalin
Trial: 35249270
Drug: Metformin add-on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin add-on insulin therapy
Trial: 35973668
Drug: Riboflavin 50
RxNorm normalized name: riboflavin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riboflavin 50 mg daily
Trial: 35973668
Drug: Riboflavin 100
RxNorm normalized name: riboflavin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riboflavin 100 mg daily
Trial: 33472913
Drug: Guadecitabine 20
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Guadecitabine 20 mg/m2, days 1-5, combined with gemcitabine (1,000 mg/m2, i.v., days 8 + 15) and cisplatin (70 mg/m2, i.v., day 8)
Trial: 35394800
Drug: selinexor (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: selinexor (60 mg) twice weekly in 6-week cycles
Trial: 34097045
Drug: HMGCR GRS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMGCR GRS equivalent to a 10‐mg/dL decrease in LDL cholesterol
Trial: 32605578
Drug: Bifidobacterium quadruple
RxNorm normalized name: BIFIDOBACTERIUM
DrugBank: Bifidobacterium spp. (DB18530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifidobacterium quadruple viable tablet
Trial: 35107050
Drug: AVT02 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVT02 (40 mg dose)
Trial: 35107050
Drug: EU-reference product
RxNorm normalized name: chlorine dioxide
DrugBank: Chlorine dioxide (DB12453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EU-reference product (adalimumab) (40 mg dose)
Trial: 35107050
Drug: US-reference product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US-reference product (adalimumab) (40 mg dose)
Trial: 35107050
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment arms (AVT02, EU-reference, US-reference)
Trial: 32576225
Drug: Atezolizumab (anti-PD-L1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (anti-PD-L1 antibody)
Trial: 32576225
Drug: Pegylated liposomal
RxNorm normalized name: doxorubicin HCl pegylated liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated liposomal doxorubicin (PLD 20 mg/m2 intravenously every 2nd week) + cyclophosphamide (50 mg per day, first 2 weeks in each 4 week cycle) + Atezolizumab
Trial: 32576225
Drug: Pegylated liposomal
RxNorm normalized name: doxorubicin HCl pegylated liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated liposomal doxorubicin (PLD 20 mg/m2 intravenously every 2nd week) + cyclophosphamide (50 mg per day, first 2 weeks in each 4 week cycle) + Placebo
Trial: 34742230
Drug: LTN 200
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LTN 200 mg
Trial: 34742230
Drug: LTN 100
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LTN 100 mg
Trial: 34742230
Drug: LTN 200
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LTN 200 mg, LTN 100 mg, LTN 50 mg
Trial: 35414799
Drug: Probiotics combined
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics combined with standard triple therapy (Group B)
Trial: 35414799
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple therapy (Group A)
Trial: 32252103
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of multi-joint and single-joint (MJ+SJ) exercises
Trial: 34986506
Drug: SQ sublingual
RxNorm normalized name: Sublingual Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQ sublingual immunotherapy tablets for grass pollen allergy
Trial: 34986506
Drug: SQ sublingual
RxNorm normalized name: Sublingual Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQ sublingual immunotherapy tablets for tree pollen allergy
Trial: 32348531
Drug: Anti-VEGF agents
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-VEGF agents
Trial: 33496413
Drug: Dexmedetomidine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.5 mg / kg / h)
Trial: 33496413
Drug: Remifentanil (50‐100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (50‐100 μg / kg / h)
Trial: 32805184
Drug: Statin+high‐dose EPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin+high‐dose EPA (1800 mg/day)
Trial: 32805184
Drug: Statin+EPA (930
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin+EPA (930 mg/day)+DHA (750 mg/day)
Trial: 34755785
Drug: Ibuprofen/Caffeine
RxNorm normalized name: Ibuprofen/Caffeine/Vitamins B1, B2, B6, & B12 400 mg-65 mg-25 mg-6.25 mg-25 mg-125 mcg ORAL COMBINATION PACKAGE (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen/Caffeine
Trial: 35272897
Drug: Intraosseous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraosseous morphine (10 mg) with standard IO antibiotic injection
Trial: 35272897
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received standard IO antibiotic injection
Trial: 33244562
Drug: MCP® BCMC®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCP® BCMC® strains (administered twice daily)
Trial: 33539946
Drug: Chemotherapy (topotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (topotecan or amrubicin)
Trial: 33168839
Drug: Laxative immediately
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laxative immediately followed by Clostridium butyricum (CB) administration for 2 weeks (LP)
Trial: 33168839
Drug: Laxative, interval
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laxative, interval of 2 weeks and CB administration for 2 weeks (L2P)
Trial: 33168839
Drug: CB administration
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CB administration for 2 weeks (P)
Trial: 33821332
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (8000 IU daily)
Trial: 33761932
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of transcranial pulsed current stimulation (tPCS) at 400 Hz, 1 mA and transcutaneous electrical nerve stimulation (TENS) at 400 Hz, max 10 mA for 30 min, followed by 30 min of physiotherapy five times per week for 12 weeks.
Trial: 36446452
Drug: Surgery and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery and adjuvant chemotherapy
Trial: 35403245
Drug: Veliparib in
RxNorm normalized name: veliparib
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib in combination with carboplatin/paclitaxel (120 mg twice daily)
Trial: 35809704
Drug: β‐caryophyllene (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β‐caryophyllene (100 mg/daily with meal)
Trial: 32535732
Drug: IL-6 inhibitors
RxNorm normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-6 inhibitors (tocilizumab, sarilumab, siltuximab)
Trial: 32535732
Drug: IL-6 inhibitors
RxNorm normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-6 inhibitors (tocilizumab, sarilumab)
Trial: 36220198
Drug: Incentivized lifestyle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incentivized lifestyle intervention program with stepwise addition of metformin
Trial: 33471963
Drug: Telephone-delivered adherence
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-delivered adherence therapy (8 weekly 30-min sessions)
Trial: 36106493
Drug: Intranasal isotonic
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal isotonic saline (Group C)
Trial: 36106493
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine 0.5 μg kg-1 (Group D0.5)
Trial: 36106493
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine 1.0 μg kg-1 (Group D1.0)
Trial: 36106493
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine 1.5 μg kg-1 (Group D1.5)
Trial: 36106493
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine 2.0 μg kg-1 (Group D2.0)
Trial: 36106493
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine (ED95)
Trial: 34225282
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group continued to receive anticholinergic drugs for 90 days